18 December 2025 in European Respiratory Journal
Question: Chronic lung allograft dysfunction (CLAD) is the leading cause of late graft failure after lung transplantation. Fibroblast activation protein (FAP) is selectively upregulated in activated fibroblasts under fibrotic conditions. We asked whether FAP expression is increased in CLAD and whether it can serve as an early diagnostic marker. Materials and methods: We performed single-cell RNA sequencing on two murine orthotopic lung transplant models (C57BL/6→C57BL/10 and BALB/c→C57BL/6) and human lung tissue from five controls and five patients with CLAD. We quantified FAP expression by immunohistochemistry in transbronchial biopsies from 240 lung transplant recipients (62 with CLAD and 178 without CLAD). Receiver-operating characteristic curves determined an optimal FAP-positive area threshold. Kaplan–Meier analysis and Cox proportional hazards models assessed the association between FAP positivity and CLAD. Results: In both murine and human single-cell data, FAP expression was confined to pathogenic fibroblast subsets and was significantly elevated in CLAD. In the clinical cohort, a threshold of 10.8% FAP-positive area discriminated chronic dysfunction with an area under the curve of 0.78 (95% CI 0.72–0.85), sensitivity of 65% and specificity of 84%. FAP positivity predicted shorter CLAD-free survival (p<0.0001) and overall survival (p=0.03). The hazard ratio for CLAD was 5.23 (95% CI 3.11–8.82; p<0.001), remaining significant after multivariable adjustment (hazard ratio 5.43, 95% CI 3.22–9.16; p<0.001). Answer: FAP expression is elevated in CLAD and is associated with subsequent CLAD and survival. Tissue FAP may enable early risk stratification and inform clinical surveillance; however, given its moderate discrimination, prospective validation in multicentre cohorts is warranted.
27 December 2023 in Respiratory Investigation
16 November 2023 in American Journal of Transplantation
Growing evidence implicates complement in the pathogenesis of primary graft dysfunction (PGD). We hypothesized that early complement activation postreperfusion could predispose to severe PGD grade 3 (PGD-3) at 72 hours, which is associated with worst posttransplant outcomes. Consecutive lung transplant patients (n = 253) from January 2018 through June 2023 underwent timed open allograft biopsies at the end of cold ischemia (internal control) and 30 minutes postreperfusion. PGD-3 at 72 hours occurred in 14% (35/253) of patients; 17% (44/253) revealed positive C4d staining on postreperfusion allograft biopsy, and no biopsy-related complications were encountered. Significantly more patients with PGD-3 at 72 hours had positive C4d staining at 30 minutes postreperfusion compared with those without (51% vs 12%, P < .001). Conversely, patients with positive C4d staining were significantly more likely to develop PGD-3 at 72 hours (41% vs 8%, P < .001) and experienced worse long-term outcomes. In multivariate logistic regression, positive C4d staining remained highly predictive of PGD-3 (odds ratio 7.92, 95% confidence interval 2.97-21.1, P < .001). Hence, early complement deposition in allografts is highly predictive of PGD-3 at 72 hours. Our data support future studies to evaluate the role of complement inhibition in patients with early postreperfusion complement activation to mitigate PGD and improve transplant outcomes.
1 July 2024 in Journal of Thoracic Disease
Background: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) therapy is being increasingly used as respiratory support for patients with severe coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS). However, the long-term outcome of VV-ECMO as a bridge to lung transplantation in COVID-19-associated ARDS remains unclear, hence the purpose of this study aimed to evaluate its long-term outcome, safety, and feasibility. Methods: This was a retrospective cohort study from an institutional lung transplantation database between June 2020 and June 2022. Data on demographics, pre-transplantation laboratory values, postoperative outcomes, preoperative and postoperative transthoracic echocardiography findings, and survival rates were collected. Chi-square, Mann-Whitney U, Student’s t, Kaplan-Meier, and Wilcoxon signed-rank tests were used for analysis. Results: Twenty-five patients with COVID-19-associated ARDS underwent lung transplant surgery with VV-ECMO bridge. Unfortunately, six patients with COVID-19-associated ARDS using VV-ECMO died while waiting for transplantation during the same study period. Patients with VV-ECMO bridge were a more severe cohort than 16 patients without VV-ECMO bridge (lung allocation score: 88.1 vs. 74.9, P<0.001). These patients had longer intensive care unit and hospital stays (P=0.03 and P=0.02, respectively) and a higher incidence of complications after lung transplantation. The one-year survival rate of patients with VV-ECMO bridge was lower than that of patients without (78.3% vs. 100.0%, P=0.06), but comparable to that of patients with other lung transplant indications (84.2%, P=0.95). Echocardiography showed a decrease in the right ventricular systolic pressure (P=0.01), confirming that lung transplantation improved right heart function. Conclusions: Our findings suggest that VV-ECMO can be used to safely bridge patients with COVID-19 associated ARDS with right heart failure.
1 November 2025 in Journal of Thoracic Disease
Original Article Risk factors and perioperative complications associated with deep venous thrombosis and pulmonary embolism after lung transplantation Nathan T. Kim, Yudai Miyashita, Taisuke Kaihou, Joshua T. Kim, Chitaru Kurihara
1 September 2025 in Journal of Thoracic Disease
Background: Sternal wound dehiscence and infection affect up to one-third of lung transplant recipients and are associated with mediastinitis, prolonged hospitalization, impaired graft function, and increased mortality. Despite advances in perioperative care, contemporary data on the patient- and procedure-related risk factors for these complications after lung transplantation remain scarce. Therefore, this study aimed to identify independent pre- and postoperative predictors of sternal dehiscence/infection in modern lung-transplant practice. Methods: A retrospective review of the lung transplant database identified 290 consecutive patients who underwent lung transplantation with sternotomy from 2018 to 2024. A cohort of 33 with sternal dehiscence/infection and 257 patients without sternal complications were compared. The patient demographics, pre-operative medical conditions, surgical factors, and postoperative outcomes were analyzed. Univariate and multivariate logistic regression analysis was used to predict sternal complications after lung transplantation. Results: The incidence of sternal dehiscence/infection was 11.4%, and the median interval between initial lung transplantation and reoperation for sternal complications was 99 days. In the univariate analysis, the sternal complication was more common in men, patients who developed postoperative acute kidney injury (AKI), and required post-operative veno-venous extracorporeal membrane oxygenation (ECMO). The multivariate analysis showed preoperative factors such as being female were associated with a lower risk of sternal complications [odds ratio (OR) =0.39; 95% confidence interval (CI): 0.16–0.94; P=0.04] while post-operative complications such as AKI increased the risk for sternal complications (OR =2.67; 95% CI: 1.08–6.61; P=0.03). Conclusions: Sternal complications after lung transplantation were associated with patient factors such as male and post-operative complications such as renal failures. Patients with these risk factors may develop impaired sternal healing, requiring additional measurements to prevent sternal complications.